IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v14y2005i4p339-347.html
   My bibliography  Save this item

Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.
  2. Xuanqian Xie & Alexis K. Schaink & Sichen Liu & Myra Wang & Andrei Volodin, 2023. "Understanding bias in probabilistic analysis in model-based health economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 307-319, March.
  3. Samer A. Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2015. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 35(3), pages 351-360, April.
  4. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
  5. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.
  6. Benjamin Thorpe & Orlagh Carroll & Linda Sharples, 2018. "Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model," Medical Decision Making, , vol. 38(2), pages 150-162, February.
  7. Belfiore, Alessandra & Scaletti, Alessandro & Lavorato, Domenica & Cuccurullo, Corrado, 2023. "The long process by which HTA became a paradigm: A longitudinal conceptual structure analysis," Health Policy, Elsevier, vol. 127(C), pages 74-79.
  8. Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson, 2018. "Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models," PharmacoEconomics, Springer, vol. 36(12), pages 1421-1426, December.
  9. Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen, 2019. "A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 37(6), pages 829-843, June.
  10. Lionel Perrier & Anne Lefranc & David Pérol & Philippe Quittet & Aline Schmidt-Tanguy & Carole Siani & Christian Peretti & Bertrand Favier & Pierre Biron & Philippe Moreau & Jacques Bay & Séverine Lis, 2013. "Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 129-138, April.
  11. John W. Stevens, 2018. "Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?," PharmacoEconomics, Springer, vol. 36(10), pages 1135-1141, October.
  12. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
  13. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2017. "A Review of Methods for Analysis of the Expected Value of Information," Medical Decision Making, , vol. 37(7), pages 747-758, October.
  14. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
  15. Laura Bojke & Marta O. Soares & Karl Claxton & Abigail Colson & Aimée Fox & Chris Jackson & Dina Jankovic & Alec Morton & Linda D. Sharples & Andrea Taylor, 2022. "Reference Case Methods for Expert Elicitation in Health Care Decision Making," Medical Decision Making, , vol. 42(2), pages 182-193, February.
  16. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
  17. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
  18. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023.
  19. Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos, 2007. "A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK," PharmacoEconomics, Springer, vol. 25(1), pages 39-54, January.
  20. Bogdan Grigore & Jaime Peters & Christopher Hyde & Ken Stein, 2013. "Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment," PharmacoEconomics, Springer, vol. 31(11), pages 991-1003, November.
  21. Anna Heath & Mark Strong & David Glynn & Natalia Kunst & Nicky J. Welton & Jeremy D. Goldhaber-Fiebert, 2022. "Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial," Medical Decision Making, , vol. 42(2), pages 143-155, February.
  22. Sofia Dias & Alex J. Sutton & A. E. Ades & Nicky J. Welton, 2013. "Evidence Synthesis for Decision Making 2," Medical Decision Making, , vol. 33(5), pages 607-617, July.
  23. White, Nicole & Blythe, Robin, 2023. "ShinyPrior: A tool for estimating probability distributions using published evidence," OSF Preprints zf62e, Center for Open Science.
  24. Matt Stevenson & Peter Selby, 2014. "Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider," PharmacoEconomics, Springer, vol. 32(8), pages 735-743, August.
  25. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2019. "Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression," Medical Decision Making, , vol. 39(4), pages 347-359, May.
  26. Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi, 2019. "Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review," PharmacoEconomics, Springer, vol. 37(6), pages 777-818, June.
  27. Linke Li & Hawre Jalal & Anna Heath, 2024. "Accurate EVSI Estimation for Nonlinear Models Using the Gaussian Approximation Method," Medical Decision Making, , vol. 44(7), pages 787-801, October.
  28. Michelle Tew & Michael Willis & Christian Asseburg & Hayley Bennett & Alan Brennan & Talitha Feenstra & James Gahn & Alastair Gray & Laura Heathcote & William H. Herman & Deanna Isaman & Shihchen Kuo , 2022. "Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Chal," Medical Decision Making, , vol. 42(5), pages 599-611, July.
  29. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
  30. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
  31. Peter J. Dodd & Debebe Shaweno & Chu-Chang Ku & Philippe Glaziou & Carel Pretorius & Richard J. Hayes & Peter MacPherson & Ted Cohen & Helen Ayles, 2023. "Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
  32. Ji-Hee Youn & Matt D. Stevenson & Praveen Thokala & Katherine Payne & Maria Goddard, 2019. "Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models," Medical Decision Making, , vol. 39(7), pages 842-856, October.
  33. Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume, 2006. "Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 137-144, June.
  34. Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
  35. Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall, 2020. "One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit," PharmacoEconomics, Springer, vol. 38(2), pages 135-141, February.
  36. Anthony Newall & Mark Jit & Philippe Beutels, 2012. "Economic Evaluations of Childhood Influenza Vaccination," PharmacoEconomics, Springer, vol. 30(8), pages 647-660, August.
  37. Christopher McCabe & Giovanni Tramonti & Andrew Sutton & Peter Hall & Mike Paulden, 2021. "Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier," PharmacoEconomics, Springer, vol. 39(1), pages 19-24, January.
  38. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
  39. Pepijn Vemer & Lucas M. A. Goossens & Maureen P. M. H. Rutten-van Mölken, 2014. "Not Simply More of the Same," Medical Decision Making, , vol. 34(8), pages 1048-1058, November.
  40. Nicholas Graves & Katie Page & Elizabeth Martin & David Brain & Lisa Hall & Megan Campbell & Naomi Fulop & Nerina Jimmeison & Katherine White & David Paterson & Adrian G Barnett, 2016. "Cost-Effectiveness of a National Initiative to Improve Hand Hygiene Compliance Using the Outcome of Healthcare Associated Staphylococcus aureus Bacteraemia," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-17, February.
  41. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
  42. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
  43. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440, March.
  44. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023, October.
  45. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
  46. Tiago M. de Carvalho & Eveline A. M. Heijnsdijk & Luc Coffeng & Harry J. de Koning, 2019. "Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators," Medical Decision Making, , vol. 39(4), pages 405-413, May.
  47. Yevgeniy Samyshkin & Robert Kotchie & Ann-Christin Mörk & Andrew Briggs & Eric Bateman, 2014. "Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 69-82, January.
  48. Sun-Young Kim & Louise B. Russell & Anushua Sinha, 2015. "Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly," Medical Decision Making, , vol. 35(5), pages 567-569, July.
  49. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
  50. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
  51. Anna Heath & Petros Pechlivanoglou, 2022. "Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity," Medical Decision Making, , vol. 42(5), pages 649-660, July.
  52. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
  53. Adam J. N. Raymakers & John Mayo & Stephen Lam & J. Mark FitzGerald & David G. T. Whitehurst & Larry D. Lynd, 2016. "Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 409-418, August.
  54. T. I. Armina Padmasawitri & Sarah Maria Saragih & Gerardus W. Frederix & Olaf Klungel & Anke M. Hövels, 2020. "Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(2), pages 223-233, June.
  55. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
  56. Bogdan Grigore & Oriana Ciani & Florian Dams & Carlo Federici & Saskia Groot & Meilin Möllenkamp & Stefan Rabbe & Kosta Shatrov & Antal Zemplenyi & Rod S. Taylor, 2020. "Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines," PharmacoEconomics, Springer, vol. 38(10), pages 1055-1070, October.
  57. Zoë Pieters & Mark Strong & Virginia E. Pitzer & Philippe Beutels & Joke Bilcke, 2020. "A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations," Medical Decision Making, , vol. 40(5), pages 669-679, July.
  58. Shijie Ren & Jonathan Minton & Sophie Whyte & Nicholas R. Latimer & Matt Stevenson, 2018. "A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis," PharmacoEconomics, Springer, vol. 36(3), pages 341-347, March.
  59. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
  60. Laura Bojke & Bogdan Grigore & Dina Jankovic & Jaime Peters & Marta Soares & Ken Stein, 2017. "Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties," PharmacoEconomics, Springer, vol. 35(9), pages 867-877, September.
  61. Christopher H. Jackson & Laura Bojke & Simon G. Thompson & Karl Claxton & Linda D. Sharples, 2011. "A Framework for Addressing Structural Uncertainty in Decision Models," Medical Decision Making, , vol. 31(4), pages 662-674, July.
  62. Daniel Hill-McManus, 2024. "The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations," PharmacoEconomics, Springer, vol. 42(1), pages 11-18, January.
  63. Helen A. Dakin & José Leal & Andrew Briggs & Philip Clarke & Rury R. Holman & Alastair Gray, 2020. "Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data," Medical Decision Making, , vol. 40(4), pages 460-473, May.
  64. Mehdi Najafzadeh & Jorge A. Garces & Alejandra Maciel, 2017. "Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety," PharmacoEconomics, Springer, vol. 35(12), pages 1297-1310, December.
  65. Steven Edwards & Sarah Wordsworth & Mike Clarke, 2012. "Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 181-192, April.
  66. Kurinchi Gurusamy & Edward Wilson & Andrew Burroughs & Brian Davidson, 2012. "Intra-operative vs pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones," Applied Health Economics and Health Policy, Springer, vol. 10(1), pages 15-29, January.
  67. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
  68. Jagpreet Chhatwal & Tianhua He, 2015. "Economic Evaluations with Agent-Based Modelling: An Introduction," PharmacoEconomics, Springer, vol. 33(5), pages 423-433, May.
  69. Nicky J. Welton & Jason J. Madan & Deborah M. Caldwell & Tim J. Peters & Anthony E. Ades, 2014. "Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes," Medical Decision Making, , vol. 34(3), pages 352-365, April.
  70. Sofia Dias & Alex J. Sutton & Nicky J. Welton & A. E. Ades, 2013. "Evidence Synthesis for Decision Making 6," Medical Decision Making, , vol. 33(5), pages 671-678, July.
  71. Joseph F. Levy & Patrick D. Meek & Marjorie A. Rosenberg, 2015. "US-Based Drug Cost Parameter Estimation for Economic Evaluations," Medical Decision Making, , vol. 35(5), pages 622-632, July.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.